Heron Therapeutics to Present at the Leerink Partners 2015 Global Healthcare Conference

February 3, 2015 8:01 AM ET

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 3, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 8:50 a.m. ET in New York City.

A live webcast of this presentation will be available on the Company's website at www.herontx.com in the Investors section. A replay of the presentation will be archived on the site for 90 days.

About SUSTOL®

Heron's lead investigational product candidate, SUSTOL® (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT_3 receptor antagonist approved for the prevention of delayed-onset CINV in patients receiving moderately emetogenic chemotherapy (MEC); none are approved for delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC). SUSTOL contains the 5-HT_3 receptor antagonist granisetron formulated in the Company's proprietary Biochronomer® polymer-based drug delivery platform, which has been shown in clinical studies to maintain therapeutic drug levels of SUSTOL for up to five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

About HTX-019 for Chemotherapy Induced Nausea and Vomiting

HTX-019 is a proprietary intravenous formulation of aprepitant, an NK_1 receptor antagonist. HTX-019 does not contain polysorbate 80, which may cause hypersensitivity reactions in some patients. At present, there is only one intravenous NK_1 receptor antagonist approved in the U.S. for the prevention of CINV. NK_1 receptor antagonists are used in combination with a 5-HT_3 receptor antagonist for the prevention of CINV.

About HTX-011 for Post-Operative Pain

HTX-011 is a combination of local anesthetic bupivacaine and the anti-inflammatory meloxicam in a novel formulation utilizing Heron's proprietary Biochronomer polymer-based drug delivery platform. In an animal model of post-surgical pain, HTX-011 significantly reduced pain through 72 hours.

About HTX-003 for Chronic Pain and Addiction

HTX-003 is a long-acting formulation of buprenorphine for the management of chronic pain and opioid addiction. Utilizing Heron's proprietary Biochronomer polymer-based drug delivery platform, HTX-003 is designed to maintain therapeutic drug levels of buprenorphine for 30 days following a single subcutaneous injection, with low potential for patient abuse.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company's proprietary Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. The Company's product development program also focuses

on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effect, or eliminate the drawbacks of current therapies.

Forward Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those associated with the timing of completion of the HEC study, and the results thereof, and the NDA resubmission for SUSTOL, potential regulatory approval of SUSTOL and the timing for such approval, if approved at all; risks relating to progress in research and development of HTX-019, HTX-011, HTX-003 and our other product candidate programs, including the timing of planned toxicology and clinical studies; the risk that safety and efficacy data from our clinical studies may not warrant further development of our product candidates, risks related to the launch and acceptance of new products generally; risks related to our financial position and our ability to raise additional capital to fund operations if necessary or to pursue additional business opportunities; risks related to strategic business alliances we may pursue or the potential acquisition of other products or technologies and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.

Source: Heron Therapeutics, Inc.

Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Sr. Manager, Investor Relations
jcapuzelo@herontx.com
or
Corporate Contact:
Barry D. Quart, 650-366-2626
Pharm D., Chief Executive Officer